This clinical trial is focused on studying a condition called Amyloid Light Chain (AL) Amyloidosis. This is a disease where abnormal proteins, known as amyloids, build up in organs and tissues, which can affect their normal function. The study is testing a combination of treatments that include Daratumumab, Bortezomib (marketed as VELCADE), Cyclophosphamide, and Dexamethasone Sodium Phosphate. These medications are used to target and reduce the amyloid deposits in the body.

The purpose of the study is to understand the safety of these treatments, especially concerning the heart, in people who have been newly diagnosed with AL Amyloidosis that affects the heart. The study also aims to find ways to reduce any heart-related side effects and to understand how the body processes Daratumumab, particularly in racial and ethnic minority groups. Participants in the study will receive these medications through injections or infusions over a period of time, and their health will be monitored closely to observe any changes or improvements in their condition.

Throughout the study, some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatments. The study will help gather important information on how effective and safe these treatments are for managing AL Amyloidosis, with a focus on improving heart health and overall survival. The findings from this study could lead to better treatment strategies for people living with this condition.